v-2.jpg
logo-1-new.png

About Us

Amytrx is a clinical-stage biopharmaceutical company advancing the next generation of new anti-inflammatory peptide therapies for patients suffering from chronic inflammatory diseases. We are a group of dedicated scientific, medical, and business professionals all deeply committed to positively transforming the health and lives of patients.  

Leadership Team

Image-empty-state.png

Matthew A. Gonda, Ph.D.

President, CEO and Founder

Image-empty-state.png

Randall B. Riggs, MBA

Chief Business Officer

Image-empty-state.png

Shima Joshi, Ph.D.

VP, Regulatory Affairs

Image-empty-state.png

Vernon L. Alvarez, Ph.D.

SVP, Research & Development

Image-empty-state.png

Satish Joshi, Ph.D.

VP, Peptide Chemistry

Image-empty-state.png

Maya Frutiger

VP, Corporate Affairs

Image-empty-state.png

Danny O. Helton, Ph.D.

VP, Chemistry & Manufacturing

Board of Directors 

Matthew A. Gonda, Ph.D.

President, CEO and Founder

Lawrence W. Greer, DDS, MBA

Director

G. William Coble, II

Director

Daniel D. Canale, M.D.

Director

Thomas G. Andrews

Director and Founder

Dennis J. Carlo, Ph.D.

Director

Raymond Pirtle, Jr.

Director

Founders

Matthew A. Gonda, Ph.D.

President, CEO and Founder

Thomas G. Andrews

Director and Founder

Jacek Hawiger, M.D., Ph.D.

Founder